Browse > Article
http://dx.doi.org/10.14348/molcells.2021.0130

TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in Leiomyosarcoma  

Lee, Eun-Young (Division of Translational Science, Research Institute, National Cancer Center)
Kim, Minjeong (Division of Translational Science, Research Institute, National Cancer Center)
Choi, Beom K. (Biomedicine Production Branch, Research Institute, National Cancer Center)
Kim, Dae Hong (Division of Convergence Technology, Research Institute, National Cancer Center)
Choi, Inho (Department of Medical Biotechnology, Yeungnam University)
You, Hye Jin (Division of Translational Science, Research Institute, National Cancer Center)
Publication Information
Molecules and Cells / v.44, no.11, 2021 , pp. 784-794 More about this Journal
Abstract
Leiomyosarcoma (LMS) is a mesenchymal malignancy with a complex karyotype. Despite accumulated evidence, the factors contributing to the development of LMS are unclear. Here, we investigated the role of tight-junction protein 1 (TJP1), a membrane-associated intercellular barrier protein during the development of LMS and the tumor microenvironment. We orthotopically transplanted SK-LMS-1 cells and their derivatives in terms of TJP1 expression by intramuscular injection, such as SK-LMS-1 Sh-Control cells and SK-LMS-1 Sh-TJP1. We observed robust tumor growth in mice transplanted with LMS cell lines expressing TJP1 while no tumor mass was found in mice transplanted with SK-LMS-1 Sh-TJP1 cells with silenced TJP1 expression. Tissues from mice were stained and further analyzed to clarify the effects of TJP1 expression on tumor development and the tumor microenvironment. To identify the TJP1-dependent factors important in the development of LMS, genes with altered expression were selected in SK-LMS-1 cells such as cyclinD1, CSF1 and so on. The top 10% of highly expressed genes in LMS tissues were obtained from public databases. Further analysis revealed two clusters related to cell proliferation and the tumor microenvironment. Furthermore, integrated analyses of the gene expression networks revealed correlations among TJP1, CSF1 and CTLA4 at the mRNA level, suggesting a possible role for TJP1 in the immune environment. Taken together, these results imply that TJP1 contributes to the development of sarcoma by proliferation through modulating cell-cell aggregation and communication through cytokines in the tumor microenvironment and might be a beneficial therapeutic target.
Keywords
cytokines; leiomyosarcoma; tjp1; tumor microenvironment;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Ren, W., Korchin, B., Lahat, G., Wei, C., Bolshakov, S., Nguyen, T., Merritt, W., Dicker, A., Lazar, A., Sood, A., et al. (2008). Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma. Clin. Cancer Res. 14, 5466-5475.   DOI
2 Chae, Y.K., Chang, S., Ko, T., Anker, J., Agte, S., Iams, W., Choi, W.M., Lee, K., and Cruz, M. (2018). Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). Sci. Rep. 8, 2918.   DOI
3 Chibon, F., Lagarde, P., Salas, S., Perot, G., Brouste, V., Tirode, F., Lucchesi, C., de Reynies, A., Kauffmann, A., Bui, B., et al. (2010). Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat. Med. 16, 781-787.   DOI
4 Chudasama, P., Mughal, S.S., Sanders, M.A., Hubschmann, D., Chung, I., Deeg, K.I., Wong, S.H., Rabe, S., Hlevnjak, M., Zapatka, M., et al. (2018). Integrative genomic and transcriptomic analysis of leiomyosarcoma. Nat. Commun. 9, 144.   DOI
5 Cloutier, J.M. and Charville, G.W. (2019). Diagnostic classification of soft tissue malignancies: a review and update from a surgical pathology perspective. Curr. Probl. Cancer 43, 250-272.   DOI
6 Fanning, A.S., Jameson, B.J., Jesaitis, L.A., and Anderson, J.M. (1998). The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J. Biol. Chem. 273, 29745-29753.   DOI
7 Fletcher, C.D. (2014). The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. Histopathology 64, 2-11.   DOI
8 Grivennikov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inflammation, and cancer. Cell 140, 883-899.   DOI
9 Helman, L.J. and Meltzer, P. (2003). Mechanisms of sarcoma development. Nat. Rev. Cancer 3, 685-694.   DOI
10 Babicki, S., Arndt, D., Marcu, A., Liang, Y., Grant, J.R., Maciejewski, A., and Wishart, D.S. (2016). Heatmapper: web-enabled heat mapping for all. Nucleic Acids Res. 44(W1), W147-W153.   DOI
11 Guo, X., Jo, V.Y., Mills, A.M., Zhu, S.X., Lee, C.H., Espinosa, I., Nucci, M.R., Varma, S., Forgo, E., Hastie, T., et al. (2015). Clinically relevant molecular subtypes in leiomyosarcoma. Clin. Cancer Res. 21, 3501-3511.   DOI
12 Barretina, J., Taylor, B.S., Banerji, S., Ramos, A.H., Lagos-Quintana, M., Decarolis, P.L., Shah, K., Socci, N.D., Weir, B.A., Ho, A., et al. (2010). Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat. Genet. 42, 715-721.   DOI
13 Cancer Genome Atlas Research Network (2017). Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell 171, 950-965.e28.   DOI
14 Kim, J., Kim, J.H., Kang, H.G., Park, S.Y., Yu, J.Y., Lee, E.Y., Oh, S.E., Kim, Y.H., Yun, T., Park, C., et al. (2018). Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets. BMC Med. Genet. 19(Suppl 1), 216.   DOI
15 Lin, H.H., Faunce, D.E., Stacey, M., Terajewicz, A., Nakamura, T., Zhang-Hoover, J., Kerley, M., Mucenski, M.L., Gordon, S., and Stein-Streilein, J. (2005). The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J. Exp. Med. 201, 1615-1625.   DOI
16 Mlecnik, B., Bindea, G., Angell, H.K., Maby, P., Angelova, M., Tougeron, D., Church, S.E., Lafontaine, L., Fischer, M., Fredriksen, T., et al. (2016). Integrative analyses of colorectal cancer show Immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity 44, 698-711.   DOI
17 Dwyer, A.R., Greenland, E.L., and Pixley, F.J. (2017). Promotion of tumor invasion by tumor-associated macrophages: the role of CSF-1-activated phosphatidylinositol 3 kinase and Src family kinase motility signaling. Cancers (Basel) 9, 68.   DOI
18 Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1.   DOI
19 Lee, E.Y., Yu, J.Y., Paek, A.R., Lee, S.H., Jang, H., Cho, S.Y., Kim, J.H., Kang, H.G., Yun, T., Oh, S.E., et al. (2020). Targeting TJP1 attenuates cell-cell aggregation and modulates chemosensitivity against doxorubicin in leiomyosarcoma. J. Mol. Med. (Berl.) 98, 761-773.   DOI
20 Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M.A., et al. (2017). Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32, 654-668.e5.   DOI
21 Martin, T.A. and Jiang, W.G. (2009). Loss of tight junction barrier function and its role in cancer metastasis. Biochim. Biophys. Acta 1788, 872-891.   DOI
22 Nirmal, A.J., Regan, T., Shih, B.B., Hume, D.A., Sims, A.H., and Freeman, T.C. (2018). Immune cell gene signatures for profiling the microenvironment of solid tumors. Cancer Immunol. Res. 6, 1388-1400.   DOI
23 Paek, A.R., Mun, J.Y., Hong, K.M., Lee, J., Hong, D.W., and You, H.J. (2017). Zinc finger protein 143 expression is closely related to tumor malignancy via regulating cell motility in breast cancer. BMB Rep. 50, 621-627.   DOI
24 Petitprez, F., de Reynies, A., Keung, E.Z., Chen, T.W., Sun, C.M., Calderaro, J., Jeng, Y.M., Hsiao, L.P., Lacroix, L., Bougouin, A., et al. (2020). B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556-560.   DOI
25 Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272.   DOI
26 Sorbye, S.W., Kilvaer, T., Valkov, A., Donnem, T., Smeland, E., Al-Shibli, K., Bremnes, R.M., and Busund, L.T. (2011). Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One 6, e14611.   DOI
27 Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H., and Vilo, J. (2019). g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47(W1), W191-W198.   DOI
28 Rusakiewicz, S., Semeraro, M., Sarabi, M., Desbois, M., Locher, C., Mendez, R., Vimond, N., Concha, A., Garrido, F., Isambert, N., et al. (2013). Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res. 73, 3499-3510.   DOI
29 Sanchez-Vega, F., Mina, M., Armenia, J., Chatila, W.K., Luna, A., La, K.C., Dimitriadoy, S., Liu, D.L., Kantheti, H.S., Saghafinia, S., et al. (2018). Oncogenic signaling pathways in The Cancer Genome Atlas. Cell 173, 321-337.e10.   DOI
30 Strowig, T., Rongvaux, A., Rathinam, C., Takizawa, H., Borsotti, C., Philbrick, W., Eynon, E.E., Manz, M.G., and Flavell, R.A. (2011). Transgenic expression of human signal regulatory protein alpha in Rag2-/-gamma(c)-/- mice improves engraftment of human hematopoietic cells in humanized mice. Proc. Natl. Acad. Sci. U. S. A. 108, 13218-13223.   DOI
31 Quail, D.F., Bowman, R.L., Akkari, L., Quick, M.L., Schuhmacher, A.J., Huse, J.T., Holland, E.C., Sutton, J.C., and Joyce, J.A. (2016). The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science 352, aad3018.   DOI
32 Zhu, Y., Knolhoff, B.L., Meyer, M.A., Nywening, T.M., West, B.L., Luo, J., Wang-Gillam, A., Goedegebuure, S.P., Linehan, D.C., and DeNardo, D.G. (2014). CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057-5069.   DOI
33 Ge, S.X., Son, E.W., and Yao, R. (2018). iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinformatics 19, 534.   DOI
34 George, S., Miao, D., Demetri, G.D., Adeegbe, D., Rodig, S.J., Shukla, S., Lipschitz, M., Amin-Mansour, A., Raut, C.P., Carter, S.L., et al. (2017). Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma. Immunity 46, 197-204.   DOI
35 Hegde, P.S. and Chen, D.S. (2020). Top 10 challenges in cancer immunotherapy. Immunity 52, 17-35.   DOI
36 Lee, S.H., Paek, A.R., Yoon, K., Kim, S.H., Lee, S.Y., and You, H.J. (2015). Tight junction protein 1 is regulated by transforming growth factor-beta and contributes to cell motility in NSCLC cells. BMB Rep. 48, 115-120.   DOI
37 Paek, A.R., Mun, J.Y., Jo, M.J., Choi, H., Lee, Y.J., Cheong, H., Myung, J.K., Hong, D.W., Park, J., Kim, K.H., et al. (2019). The role of ZNF143 in breast cancer cell survival through the NAD(P)H quinone dehydrogenase 1(-) p53(-)Beclin1 axis under metabolic stress. Cells 8, 296.   DOI
38 Gyori, D., Lim, E.L., Grant, F.M., Spensberger, D., Roychoudhuri, R., Shuttleworth, S.J., Okkenhaug, K., Stephens, L.R., and Hawkins, P.T. (2018). Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. JCI Insight 3, e120631.   DOI
39 Kim, C., Kim, I.H., Kim, S.I., Kim, Y.S., Kang, S.H., Moon, S.H., Kim, T.S., and Kim, S.K. (2011). Comparison of the intraperitoneal, retroorbital and per oral routes for F-18 FDG administration as effective alternatives to intravenous administration in mouse tumor models using small animal PET/CT studies. Nucl. Med. Mol. Imaging 45, 169-176.   DOI
40 Mata, M. and Gottschalk, S. (2015). Adoptive cell therapy for sarcoma. Immunotherapy 7, 21-35.   DOI
41 Verma, V., Paek, A.R., Choi, B.K., Hong, E.K., and You, H.J. (2019). Loss of zinc-finger protein 143 contributes to tumour progression by interleukin-8-CXCR axis in colon cancer. J. Cell. Mol. Med. 23, 4043-4053.   DOI
42 Vesely, M.D., Kershaw, M.H., Schreiber, R.D., and Smyth, M.J. (2011). Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271.   DOI
43 Zhang, X.D., Baladandayuthapani, V., Lin, H., Mulligan, G., Li, B., Esseltine, D.W., Qi, L., Xu, J., Hunziker, W., Barlogie, B., et al. (2016). Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR/JAK1/STAT3 signaling. Cancer Cell 29, 639-652.   DOI
44 Zhang, Y. and Zhang, Z. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell. Mol. Immunol. 17, 807-821.   DOI
45 Dancsok, A.R., Gao, D., Lee, A.F., Steigen, S.E., Blay, J.Y., Thomas, D.M., Maki, R.G., Nielsen, T.O., and Demicco, E.G. (2020). Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology 9, 1747340.   DOI
46 Babichev, Y., Kabaroff, L., Datti, A., Uehling, D., Isaac, M., Al-Awar, R., Prakesch, M., Sun, R.X., Boutros, P.C., Venier, R., et al. (2016). PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma. J. Transl. Med. 14, 67.   DOI
47 Thorsson, V., Gibbs, D.L., Brown, S.D., Wolf, D., Bortone, D.S., Ou Yang, T.H., Porta-Pardo, E., Gao, G.F., Plaisier, C.L., Eddy, J.A., et al. (2018). The immune landscape of cancer. Immunity 48, 812-830.e14.   DOI
48 Tuomi, S., Mai, A., Nevo, J., Laine, J.O., Vilkki, V., Ohman, T.J., Gahmberg, C.G., Parker, P.J., and Ivaska, J. (2009). PKCepsilon regulation of an alpha5 integrin-ZO-1 complex controls lamellae formation in migrating cancer cells. Sci. Signal. 2, ra32.   DOI
49 Hoos, A., Stojadinovic, A., Mastorides, S., Urist, M.J., Polsky, D., Di Como, C.J., Brennan, M.F., and Cordon-Cardo, C. (2001). High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer 92, 869-874.   DOI